Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 892

1.

Corrigendum to 'Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer' [EBioMedicine 38 (2018) 100-112].

Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G.

EBioMedicine. 2020 Jan 20;52:102630. doi: 10.1016/j.ebiom.2020.102630. [Epub ahead of print] No abstract available.

2.

Low-grade serous ovarian cancer: State of the science.

Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O'Malley DM, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fernández ML, Ray-Coquard I, Gershenson DM.

Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(19)31862-1. doi: 10.1016/j.ygyno.2019.12.033. [Epub ahead of print] Review.

PMID:
31969252
3.

Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.

Matsuo K, Machida H, Grubbs BH, Matsuzaki S, Klar M, Roman LD, Sood AK, Gershenson DM.

Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31482-9. doi: 10.1016/j.ygyno.2019.08.030. [Epub ahead of print]

PMID:
31954535
4.

Evolving population-based statistics for rare epithelial ovarian cancers.

Matsuo K, Machida H, Matsuzaki S, Grubbs BH, Klar M, Roman LD, Sood AK, Gershenson DM, Wright JD.

Gynecol Oncol. 2019 Dec 18. pii: S0090-8258(19)31781-0. doi: 10.1016/j.ygyno.2019.11.122. [Epub ahead of print]

PMID:
31954534
5.

Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions.

Xiong C, Wen Y, Zhao J, Yin D, Xu L, Chelariu-Raicu A, Yao C, Leng X, Liu J, Chaudhari RR, Zhang S, Sood AK, Li C.

Sci Rep. 2020 Jan 16;10(1):520. doi: 10.1038/s41598-020-57477-x.

6.

GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.

El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, Kabil N, Ozpolat B, Calin GA, Salama SA, Abd-Allah AR, Sood AK, Lopez-Berestein G.

Cell Signal. 2020 Jan 11;68:109539. doi: 10.1016/j.cellsig.2020.109539. [Epub ahead of print]

7.

Quantitative earthquake-like statistical properties of the flow of soft materials below yield stress.

Bera PK, Majumdar S, Ouillon G, Sornette D, Sood AK.

Nat Commun. 2020 Jan 7;11(1):9. doi: 10.1038/s41467-019-13790-2.

8.

Can stress promote the pathophysiology of brain metastases? A critical review of biobehavioral mechanisms.

Seiler A, Sood AK, Jenewein J, Fagundes CP.

Brain Behav Immun. 2019 Dec 24. pii: S0889-1591(19)30490-8. doi: 10.1016/j.bbi.2019.12.013. [Epub ahead of print] Review.

PMID:
31881262
9.

miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer.

Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, Liang M, Rader JS, Ramchandran R, You M, Sood AK, Kristensen VN, Mills GB, Pradeep S, Chaluvally-Raghavan P.

Cell Rep. 2019 Dec 24;29(13):4389-4406.e10. doi: 10.1016/j.celrep.2019.11.085.

10.

Plasmon-induced efficient hot carrier generation in graphene on gold ultrathin film with periodic array of holes: Ultrafast pump-probe spectroscopy.

Prakash G, Srivastava RK, Gupta SN, Sood AK.

J Chem Phys. 2019 Dec 21;151(23):234712. doi: 10.1063/1.5117882.

PMID:
31864269
11.

Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum.

Oncul S, Amero P, Rodriguez-Aguayo C, Calin GA, Sood AK, Lopez-Berestein G.

RNA Biol. 2019 Dec 17:1-12. doi: 10.1080/15476286.2019.1702283. [Epub ahead of print]

PMID:
31847695
12.

Predictors of survival trajectories among women with epithelial ovarian cancer.

Peres LC, Sinha S, Townsend MK, Fridley BL, Karlan BY, Lutgendorf SK, Shinn E, Sood AK, Tworoger SS.

Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31803-7. doi: 10.1016/j.ygyno.2019.12.011. [Epub ahead of print]

PMID:
31839342
13.

Mechanisms of nuclear content loading to exosomes.

Yokoi A, Villar-Prados A, Oliphint PA, Zhang J, Song X, De Hoff P, Morey R, Liu J, Roszik J, Clise-Dwyer K, Burks JK, O'Halloran TJ, Laurent LC, Sood AK.

Sci Adv. 2019 Nov 20;5(11):eaax8849. doi: 10.1126/sciadv.aax8849. eCollection 2019 Nov.

14.

Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma.

Lara OD, Krishnan S, Wang Z, Corvigno S, Zhong Y, Lyons Y, Dood R, Hu W, Qi L, Liu J, Coleman RL, Westin SN, Fleming ND, Cristini V, Rao A, Burks J, Sood AK.

Sci Rep. 2019 Nov 26;9(1):17589. doi: 10.1038/s41598-019-53872-1.

15.

Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers.

Sa JK, Hwang JR, Cho YJ, Ryu JY, Choi JJ, Jeong SY, Kim J, Kim MS, Paik ES, Lee YY, Choi CH, Kim TJ, Kim BG, Bae DS, Lee Y, Her NG, Shin YJ, Cho HJ, Kim JY, Seo YJ, Koo H, Oh JW, Lee T, Kim HS, Song SY, Bae JS, Park WY, Han HD, Ahn HJ, Sood AK, Rabadan R, Lee JK, Nam DH, Lee JW.

Genome Biol. 2019 Nov 26;20(1):253. doi: 10.1186/s13059-019-1848-3.

16.

Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma.

Kurnit KC, Sinno AK, Fellman BM, Varghese A, Stone R, Sood AK, Gershenson DM, Schmeler KM, Malpica A, Fader AN, Frumovitz M.

Obstet Gynecol. 2019 Dec;134(6):1253-1259. doi: 10.1097/AOG.0000000000003579.

PMID:
31764736
17.

Pan-cancer clinical and molecular analysis of racial disparities.

Lara OD, Wang Y, Asare A, Xu T, Chiu HS, Liu Y, Hu W, Sumazin P, Uppal S, Zhang L, Rauh-Hain JA, Sood AK.

Cancer. 2019 Nov 15. doi: 10.1002/cncr.32598. [Epub ahead of print]

PMID:
31730714
18.

Systemic inflammatory response to inhaled endotoxin does not correlate with airway response.

Sood AK, Burbank AJ, Lawson M, Zhou H, Wells HB, Peden DB, Hernandez ML.

Respir Res. 2019 Nov 12;20(1):252. doi: 10.1186/s12931-019-1227-3.

19.

A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis.

Xu X, Wang Y, Mojumdar K, Zhou Z, Jeong KJ, Mangala LS, Yu S, Tsang YH, Rodriguez-Aguayo C, Lu Y, Lopez-Berestein G, Sood AK, Mills GB, Liang H.

J Clin Invest. 2019 Dec 2;129(12):5343-5356. doi: 10.1172/JCI123396.

20.

A Solution to the Dilution: The Role for Biomarkers in Advanced Ovarian Cancer.

Handley KF, Sood AK.

Clin Cancer Res. 2020 Jan 1;26(1):9-10. doi: 10.1158/1078-0432.CCR-19-3072. Epub 2019 Oct 31.

PMID:
31672769
21.

Clinical and biological significance of EZH2 expression in endometrial cancer.

Roh JW, Choi JE, Han HD, Hu W, Matsuo K, Nishimura M, Lee JS, Kwon SY, Cho CH, Kim J, Coleman RL, Lopez-Bernstein G, Sood AK.

Cancer Biol Ther. 2020;21(2):147-156. doi: 10.1080/15384047.2019.1672455. Epub 2019 Oct 22.

PMID:
31640461
22.

Social Integration, Marital Status, and Ovarian Cancer Risk: A 20-Year Prospective Cohort Study.

Trudel-Fitzgerald C, Poole EM, Sood AK, Okereke OI, Kawachi I, Kubzansky LD, Tworoger SS.

Psychosom Med. 2019 Nov/Dec;81(9):833-840. doi: 10.1097/PSY.0000000000000747.

PMID:
31592935
23.

Design and Demonstration of High-Efficiency Quantum Well Solar Cells Employing Thin Strained Superlattices.

Welser RE, Polly SJ, Kacharia M, Fedorenko A, Sood AK, Hubbard SM.

Sci Rep. 2019 Sep 27;9(1):13955. doi: 10.1038/s41598-019-50321-x.

24.

Copper-64 Labeled PEGylated Exosomes for In Vivo Positron Emission Tomography and Enhanced Tumor Retention.

Shi S, Li T, Wen X, Wu SY, Xiong C, Zhao J, Lincha VR, Chow DS, Liu Y, Sood AK, Li C.

Bioconjug Chem. 2019 Oct 16;30(10):2675-2683. doi: 10.1021/acs.bioconjchem.9b00587. Epub 2019 Sep 27.

PMID:
31560538
25.

Experimental signatures of a nonequilibrium phase transition near the crossover point of a Langmuir monolayer.

Bera PK, Kandar AK, Krishnaswamy R, Sood AK.

J Phys Condens Matter. 2019 Sep 6;31(50):504004. doi: 10.1088/1361-648X/ab4235. [Epub ahead of print]

PMID:
31491774
26.

Successful Treatment of PAPA Syndrome with Dual Adalimumab and Tacrolimus Therapy.

Sood AK, McShane DB, Googe PB, Wu EY.

J Clin Immunol. 2019 Nov;39(8):832-835. doi: 10.1007/s10875-019-00685-6. Epub 2019 Aug 30. No abstract available.

27.

Placenta-derived extracellular vesicles induce preeclampsia in mouse models.

Han C, Wang C, Chen Y, Wang J, Xu X, Hilton T, Cai W, Zhao Z, Wu Y, Li K, Houck K, Liu L, Sood AK, Wu X, Xue F, Li M, Dong JF, Zhang J.

Haematologica. 2019 Aug 22. pii: haematol.2019.226209. doi: 10.3324/haematol.2019.226209. [Epub ahead of print]

28.

6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.

Yang H, Shu Z, Jiang Y, Mao W, Pang L, Redwood A, Jeter-Jones SL, Jennings NB, Ornelas A, Zhou J, Rodriguez-Aguayo C, Bartholomeusz G, Iles LR, Zacharias NM, Millward SW, Lopez-Berestein G, Le XF, Ahmed AA, Piwnica-Worms H, Sood AK, Bast RC, Lu Z.

Clin Cancer Res. 2019 Sep 15;25(18):5702-5716. doi: 10.1158/1078-0432.CCR-18-3448. Epub 2019 Aug 7.

PMID:
31391192
29.

Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer.

Shuford S, Wilhelm C, Rayner M, Elrod A, Millard M, Mattingly C, Lotstein A, Smith AM, Guo QJ, O'Donnell L, Elder J, Puls L, Weroha SJ, Hou X, Zanfagnin V, Nick A, Stany MP, Maxwell GL, Conrads T, Sood AK, Orr D, Holmes LM, Gevaert M, Crosswell HE, DesRochers TM.

Sci Rep. 2019 Aug 1;9(1):11153. doi: 10.1038/s41598-019-47578-7.

30.

Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?

Chelariu-Raicu A, Coleman RL, Sood AK.

Oncology (Williston Park). 2019 Jul 16;33(7). pii: 629378.

31.

Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.

Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JMG, Dizon T, Coleman RL, Cole SW, Sood AK.

Gynecol Oncol. 2019 Sep;154(3):524-530. doi: 10.1016/j.ygyno.2019.07.004. Epub 2019 Jul 25.

PMID:
31353053
32.

Chromosomal Instability in Tumor Initiation and Development.

Bach DH, Zhang W, Sood AK.

Cancer Res. 2019 Aug 15;79(16):3995-4002. doi: 10.1158/0008-5472.CAN-18-3235. Epub 2019 Jul 26. Review.

PMID:
31350294
33.

Identifying and targeting angiogenesis-related microRNAs in ovarian cancer.

Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Bayraktar R, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, Lacko AG, Sood AK.

Oncogene. 2019 Aug;38(33):6095-6108. doi: 10.1038/s41388-019-0862-y. Epub 2019 Jul 9.

PMID:
31289363
34.

Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options.

Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN.

Oncotarget. 2019 May 28;10(37):3533-3546. doi: 10.18632/oncotarget.26947. eCollection 2019 May 28.

35.

Author Correction: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.

Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan Y.

Nature. 2019 Jun;570(7761):E51. doi: 10.1038/s41586-019-1266-4.

PMID:
31127195
36.

Advancing Drug Development in Gynecologic Malignancies.

Beaver JA, Coleman RL, Arend RC, Armstrong DK, Bala S, Mills GB, Sood AK, Herzog TJ.

Clin Cancer Res. 2019 Aug 15;25(16):4874-4880. doi: 10.1158/1078-0432.CCR-19-0619. Epub 2019 May 24.

PMID:
31126961
37.

Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2019 May 15;25(10):3194. doi: 10.1158/1078-0432.CCR-19-1132. No abstract available.

PMID:
31092618
38.

Corrigendum: FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair.

Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS.

Carcinogenesis. 2019 Jul 20;40(7):936. doi: 10.1093/carcin/bgz062. No abstract available.

39.

Pan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells.

McGuire MH, Herbrich SM, Dasari SK, Wu SY, Wang Y, Rupaimoole R, Lopez-Berestein G, Baggerly KA, Sood AK.

EBioMedicine. 2019 May;43:127-137. doi: 10.1016/j.ebiom.2019.04.045. Epub 2019 May 2.

40.

Strength of Mechanical Memories is Maximal at the Yield Point of a Soft Glass.

Mukherji S, Kandula N, Sood AK, Ganapathy R.

Phys Rev Lett. 2019 Apr 19;122(15):158001. doi: 10.1103/PhysRevLett.122.158001.

PMID:
31050530
41.

Editorial: Cardio-Oncology: From Bench to Bedside.

Abe JI, Sood AK, Martin JF.

Front Cardiovasc Med. 2019 Apr 10;6:37. doi: 10.3389/fcvm.2019.00037. eCollection 2019. No abstract available.

42.

Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.

Gunaratne PH, Pan Y, Rao AK, Lin C, Hernandez-Herrera A, Liang K, Rait AS, Venkatanarayan A, Benham AL, Rubab F, Kim SS, Rajapakshe K, Chan CK, Mangala LS, Lopez-Berestein G, Sood AK, Rowat AC, Coarfa C, Pirollo KF, Flores ER, Chang EH.

Cancer. 2019 Jul 15;125(14):2409-2422. doi: 10.1002/cncr.32053. Epub 2019 Apr 23.

43.

Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients.

Cuneo MG, Szeto A, Schrepf A, Kinner EM, Schachner BI, Ahmed R, Thaker PH, Goodheart M, Bender D, Cole SW, McCabe PM, Sood AK, Lutgendorf SK, Mendez AJ.

Psychoneuroendocrinology. 2019 Aug;106:244-251. doi: 10.1016/j.psyneuen.2019.04.007. Epub 2019 Apr 6.

PMID:
31005045
44.

Trapping and sorting active particles: Motility-induced condensation and smectic defects.

Kumar N, Gupta RK, Soni H, Ramaswamy S, Sood AK.

Phys Rev E. 2019 Mar;99(3-1):032605. doi: 10.1103/PhysRevE.99.032605.

PMID:
30999541
45.

exRNA Atlas Analysis Reveals Distinct Extracellular RNA Cargo Types and Their Carriers Present across Human Biofluids.

Murillo OD, Thistlethwaite W, Rozowsky J, Subramanian SL, Lucero R, Shah N, Jackson AR, Srinivasan S, Chung A, Laurent CD, Kitchen RR, Galeev T, Warrell J, Diao JA, Welsh JA, Hanspers K, Riutta A, Burgstaller-Muehlbacher S, Shah RV, Yeri A, Jenkins LM, Ahsen ME, Cordon-Cardo C, Dogra N, Gifford SM, Smith JT, Stolovitzky G, Tewari AK, Wunsch BH, Yadav KK, Danielson KM, Filant J, Moeller C, Nejad P, Paul A, Simonson B, Wong DK, Zhang X, Balaj L, Gandhi R, Sood AK, Alexander RP, Wang L, Wu C, Wong DTW, Galas DJ, Van Keuren-Jensen K, Patel T, Jones JC, Das S, Cheung KH, Pico AR, Su AI, Raffai RL, Laurent LC, Roth ME, Gerstein MB, Milosavljevic A.

Cell. 2019 Apr 4;177(2):463-477.e15. doi: 10.1016/j.cell.2019.02.018.

46.

Small RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation.

Srinivasan S, Yeri A, Cheah PS, Chung A, Danielson K, De Hoff P, Filant J, Laurent CD, Laurent LD, Magee R, Moeller C, Murthy VL, Nejad P, Paul A, Rigoutsos I, Rodosthenous R, Shah RV, Simonson B, To C, Wong D, Yan IK, Zhang X, Balaj L, Breakefield XO, Daaboul G, Gandhi R, Lapidus J, Londin E, Patel T, Raffai RL, Sood AK, Alexander RP, Das S, Laurent LC.

Cell. 2019 Apr 4;177(2):446-462.e16. doi: 10.1016/j.cell.2019.03.024.

PMID:
30951671
47.

The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research.

Das S; Extracellular RNA Communication Consortium, Ansel KM, Bitzer M, Breakefield XO, Charest A, Galas DJ, Gerstein MB, Gupta M, Milosavljevic A, McManus MT, Patel T, Raffai RL, Rozowsky J, Roth ME, Saugstad JA, Van Keuren-Jensen K, Weaver AM, Laurent LC.

Cell. 2019 Apr 4;177(2):231-242. doi: 10.1016/j.cell.2019.03.023. Review.

PMID:
30951667
48.

GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.

Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK.

Mol Cancer Ther. 2019 May;18(5):969-979. doi: 10.1158/1535-7163.MCT-18-0770. Epub 2019 Mar 29.

PMID:
30926640
49.

Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis.

Azam SH, Porrello A, Harrison EB, Leslie PL, Liu X, Waugh TA, Belanger A, Mangala LS, Lopez-Berestein G, Wilson HL, McCann JV, Kim WY, Sood AK, Liu J, Dudley AC, Pecot CV.

Oncogene. 2019 Jun;38(26):5191-5210. doi: 10.1038/s41388-019-0786-6. Epub 2019 Mar 27.

50.

Circular RNAs in Cancer.

Bach DH, Lee SK, Sood AK.

Mol Ther Nucleic Acids. 2019 Jun 7;16:118-129. doi: 10.1016/j.omtn.2019.02.005. Epub 2019 Feb 16. Review.

Supplemental Content

Loading ...
Support Center